• Ep. 253 - IPOs, GLP-1 & Obesity, AI & Biotech

  • Sep 17 2024
  • Length: 33 mins
  • Podcast

Ep. 253 - IPOs, GLP-1 & Obesity, AI & Biotech

Listen for free

View show details

  • Summary

  • On the latest BioCentury This Week podcast, BioCentury’s editors assess the shifting market for biotech IPOs, including the profiles of the three companies that went public on NASDAQ last week, the aftermarket performance of the year's IPO class, and the prospects for more companies to make their own debut in the coming months. BioCentury’s editors also discuss whether the rush to GLP-1s for obesity will mirror the development of PD-1s for cancer and the impact on biopharma of the recent mainstream expansion of AI. This episode of BioCentury This Week was sponsored by Parexel Biotech.

    View full story: https://www.biocentury.com/article/653538

    00:01 - Sponsor Message: Parexel Biotech
    01:30 - IPOs
    10:56 - GLP-1 & Obesity
    22:18 - AI & Biotech

    To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.

    Reach us by sending a text
    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2
Show more Show less

What listeners say about Ep. 253 - IPOs, GLP-1 & Obesity, AI & Biotech

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available